Durata Therapeutics, Inc., a pharmaceutical company focused on treating infectious diseases, will move some of its operations from New Jersey to Branford and will receive $2.25 million in grants from Connecticut to make the move.
The company is based in Chicago, Illinois and will create up to 80 new, full-time jobs in Connecticut when it relocates its research and development, clinical and regulatory operations from New Jersey to Branford, according to Gov. Dannel Malloy.
“With the addition of Durata Therapeutics, we are further cementing the state as a destination for health and life science companies. Connecticut will continue to cultivate new investment, attract new talent, and work with our entrepreneurs to develop our workforce and strengthen our state’s position as a global leader in this rapidly expanding field,” Malloy said.
Funds are expected to be approved at the upcoming meeting of the State Bond Commission on Oc. 3.
According to Malloy’s administration, the total capital investment in Connecticut over the next 10 years is estimated to be $13 million, including $2 million of state assistance provided by the Department of Economic and Community Development, to be used for leasehold improvements; research and development; furniture, fixtures and equipment; relocation costs; and other project-related expenses, and will be disbursed based on job creation milestones. The remaining $250,000 will be provided as a training grant.
Malloy has made a push for bioscience companies and launched the Bioscience Connecticut initiative last year.
Durata acquired the rights to a pharmaceutical drug and two other products by acquiring Vicuron Pharmaceuticals from Pfizer. It is currently in the late stages of development of dalbavancin for acute bacterial skin and skin structure infections, or abSSSI, including MRSA, according to a news release.
